Half of children with familial hypercholesterolaemia were not at their LDL goal

Design

cross-sectional analysis of a national disease registry

Population

341 children and adolescents under 18 with familial hypercholesterolaemia at 17 Australian lipid clinics, mean age 11.9 years

Primary outcome

attainment of the guideline-recommended LDL cholesterol goal

Effect

48.3% at goal; mean LDL 6.2 mmol/L untreated and 3.8 treated; ezetimibe combination in 12.7%

Familial hypercholesterolaemia is the strongest argument in paediatrics for treating an asymptomatic child, because the arterial damage accumulates from childhood. This cross-sectional analysis of the Australian National FH Registry covers 341 children and adolescents under 18 attending 17 specialist lipid clinics between February 2015 and March 2026 — a best-case population, already in specialist care.

Mean age at enrolment was 11.9 years, which is later than guidelines recommend starting treatment, and 53.5% were index cases rather than found by cascade testing. Genetic testing had been done in 52.6%. Mean untreated LDL cholesterol was 6.2 mmol/L. At follow-up 85.4% were on lipid-lowering therapy and 91.3% of those on a moderate- or high-intensity statin, but only 12.7% were on ezetimibe in combination. Mean treated LDL cholesterol was 3.8 mmol/L, and only 48.3% reached the guideline goal. Lipoprotein(a) had been tested in 33.7%.

The gap is not diagnosis followed by neglect; it is diagnosis followed by monotherapy. A statin alone rarely takes an untreated LDL of 6.2 mmol/L to target, and ezetimibe is cheap, well tolerated in children and barely used here. For Indian practice the same logic applies with an added step: cascade testing of first-degree relatives is the highest-yield action available after an index diagnosis, and it costs a lipid profile.

• Add ezetimibe rather than accepting a statin-only result above goal
• Do cascade testing of parents and siblings at the index diagnosis, not at the next visit
• Measure lipoprotein(a) once — it changes risk assessment and never needs repeating
• Record the treatment goal in the notes so the next clinician knows whether you are at it
• Start treatment at the guideline-recommended age rather than deferring to adolescence

Why it matters

These children were all under specialist care, so the shortfall is in what is prescribed, not in whether they are found.

Don't overread it

This is registry data from specialist clinics — it describes practice, and cannot show what outcomes the missed goals produce.

The statistics, in plain English

The single most informative pair of numbers is the untreated mean of 6.2 mmol/L against the treated mean of 3.8 — a substantial fall that still leaves most children short of goal, which tells you the problem is dose and combination rather than adherence alone. Proportions from a registry describe the clinics that contribute to it, and specialist centres are the ones most likely to be doing this well, so the national picture is probably worse rather than better.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.